~~31. (amended) A method of treating large cell anaplastic lymphoma (LCAL), comprising administering an effective amount of a soluble CD30-L [according to claim 19] to a human afflicted with LCAL.~~

Please add new claims 32 to 39, as follows:

32. A purified oligomer comprising CD30 ligand (CD30-L) polypeptides, wherein the CD30-L polypeptides are each selected from the group consisting of:

a) the murine CD30-L of SEQ ID NO:6;

b) the murine CD30-L of SEQ ID NO:19;

c) the human CD30-L of SEQ ID NO:8;

d) the human CD30-L of SEQ ID NO:23; and

e) a fragment of the CD30-L of (a), (b), (c), or (d);

wherein said oligomer binds CD30.

33. An oligomer according to claim 32, wherein said oligomer comprises three CD30-L polypeptides.

34. An oligomer according to claim 32, wherein each of the CD30-L polypeptides is a soluble fragment of the human CD30-L of SEQ ID NO:8 or SEQ ID NO:23.

35. An oligomer according to claim 34, wherein each of the CD30-L polypeptides is selected from the group consisting of a polypeptide comprising the extracellular domain of the human CD30-L of SEQ ID NO:23, and a fragment of said extracellular domain, wherein said fragment binds CD30.

36. An oligomer according to claim 34, wherein said oligomer comprises three CD30-L polypeptides.

37. An oligomer according to claim 35, wherein said oligomer comprises three CD30-L polypeptides.

38. An oligomer according to claim 32, wherein each of the CD30-L polypeptides is selected from the group consisting of:

a) a soluble CD30-L polypeptide comprising the extracellular domain of a CD30-L, encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:18 or SEQ ID NO:22 under moderately stringent conditions of 55°C in 5X SSC, and

14